使用經皮冠狀動脈介入治療(PCI)的支架置放術仍然是治療有症狀冠狀動脈疾病的主要技術。自從1970 年代中期引入PCI 以來，該技術的創新(例如冠狀動脈支架和抗血小板的治療)一直在不斷完善，以克服諸如支架內再狹窄(即開發藥物洗脫支架(DES))的局限性。鎂離子被認為是生物可吸收血管支架(BRS)的有淺在力的生物可降解材料。另外，與血管內超聲(IVUS)相比，光學同調斷層掃描(OCT)的分辨率更高，通常可更好地描繪每個結構。因此，OCT已成為基於導管的顯像技術，可以為PCI 中的生物可降解性鎂合金支架植入過程提供實用臨床導引(安全性和潛在的未來前景)。

Percutaneous coronary intervention (PCI) using stents continues to be the dominant means by which symptomatic coronary disease is treated. Since PCI was introduced in the mid-1970s, innovation of this technology (e.g., coronary stent and anti-platelet therapy) is constantly being refined to overcome limitations such as in-stent restenosis (i.e., development of drug eluting stent (DES)).Magnesium is considered as an attractive biodegradable material to create coronary bioresorbable vascular scaffolds (BRS). The higher resolution of Optical coherence tomography (OCT) often provides superior delineation of each structure compared with intravascular ultrasound (IVUS). So, OCT has become a notable catheter-based imaging technology that can provide practical guidance for PCI of Drug-Eluting Resorbable Magnesium Scaffold Implantation in clinical settings (safety, and potential future perspectives).